Our in vivo results indicated a possible cascade, i.e., FGF21–FGFR1–PPARγ activation, underlying the pharmacological action of FGF21 may be involved in the regulation of junction protein expression and subsequent BBB protection in T2DM db/db mice after stroke. This evidence concerns the gene FGF21 and stroke disorder.